Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TP-03 for Demodex blepharitis
ACTRN12620000320954Phase 2Completed
- Sponsor
- Roberto González Salinas, MD
- Start
- Jan 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in blepharitis and Demodex blepharitis (DB) comparing TP-03 0.25% with Vehicle control (2 arms). Primary endpoints: Demodex mite eradication at Day 42, Cylindrical dandruff grade 0 at Day 42 and 1 more. Started Jan 2020; status: completed.
02
Drugs
lotilaner
03
Conditions
blepharitisDemodex blepharitis (DB)
Beyond the preview
Go deeper on ACTRN12620000320954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000320954.